How much funding has GangaGen received from CARB-X?

Question

Accepted Answer

GangaGen Has Secured US$7.9 Million from CARB-X for Pre-clinical Development

GangaGen has secured the third instalment of its phased funding grant from CARB-X, with the organisation having already committed US$7.9 million to support the pre-clinical development of GangaGen's Klebicin project. Further funding may become available to advance the pre-clinical phase and demonstrate safety in human volunteers, contingent on meeting specific milestones and subject to fund availability.
CARB-X Commits US$7.9 Million to Klebicin Project

CARB-X, a global initiative supporting the development of antibacterial products, has committed US$7.9 million to GangaGen's Klebicin program. This funding is specifically allocated to support the pre-clinical development phase of the project, which aims to address infections caused by multidrug-resistant Klebsiella pneumoniae.
Phased Funding Follows Milestone Achievement

The recent funding instalment represents the third phase of the grant secured by GangaGen. This disbursement follows the company's successful completion of Lead Optimization milestones within the ongoing CARB-X partnership. The Klebicin program is designed to target K. pneumoniae, a pathogen known for causing difficult-to-treat pulmonary infections and exhibiting high resistance to current antibiotics.
Potential for Additional Funding for Clinical Advancement

Beyond the current commitment, there is a possibility for additional funding from CARB-X. This potential further investment is contingent upon GangaGen meeting specific, yet-to-be-defined milestones. If these milestones are achieved and funds are available, the additional financing could support the advancement of the pre-clinical phase and enable the demonstration of safety in human volunteers.

Reading history

Hide →

This history is cleared when the page is closed.

How much funding has GangaGen received from CARB-X?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends